The Pink Ribbon Was Stolen. Here Is What It Bought.

Awareness is a product. Prevention is free.

Awareness sells. In 2010 more than 5,000 KFC restaurants went pink and gave 50 cents a bucket to Komen, $4.2 million in all, for a food nobody pretends prevents anything. Estée Lauder has raised over $99 million in the name of breast cancer since 1992 while its own products carried parabens, preservatives that act like estrogen in the body. Breast Cancer Action coined the word for it: pinkwashing. A pink ribbon on a product that contains chemicals linked to the disease it claims to fight. Prevention does not need a box. So let us look at what the ribbon sells, starting with the thing it is built around.

Who started Awareness Month: a chemical company

Denny opened his reel with the part almost nobody knows, and his sources check out. Breast Cancer Awareness Month began in October 1985 as a week-long campaign by the American Cancer Society in partnership with the pharmaceutical arm of Imperial Chemical Industries, a British conglomerate that sold pesticides and drugs out of the same house. ICI's drug business became Zeneca, then AstraZeneca; its agrochemical business became Syngenta. Same company, both sides of the ledger: the chemical and the pill for what the chemical does. Syngenta sells atrazine, the second most used weedkiller in America. In human adrenal cells, atrazine and its cousins induced aromatase, the enzyme that manufactures estrogen, about 2.5-fold (Sanderson, Toxicological Sciences, 2000) [1]. Excess estrogen is the best-established driver of hormone-positive breast cancer. In November 2025 the WHO's cancer agency reclassified atrazine as probably carcinogenic to humans, citing mammary and uterine tumors in rats; the US EPA disputes it. Our library holds women drinking atrazine-contaminated water with lower estrogen and more irregular cycles [2], the review of atrazine's aromatase effect [3], the documents showing Syngenta paid scientists and a television pundit to defend the chemical without disclosing it [4], and the other side: a 2026 modeling paper arguing aromatase induction only appears at 350 to 1,013 times the blood levels reached at regulatory exposure [5]. On the pharmaceutical side, ICI made Nolvadex, better known as tamoxifen, approved in the UK in 1973 and the most successful breast cancer drug ever sold (Jordan, Endocrine-Related Cancer, 2021). Tamoxifen is itself an IARC Group 1 carcinogen: it causes cancer of the uterus. In the trial that established it for early breast cancer, NSABP B-14, 23 of 25 endometrial cancers occurred in the tamoxifen groups and four of those women died of it [6]. The same listing says, in the same breath, that tamoxifen reduces the risk of a second breast cancer, and that is true too. The company that founded Awareness Month sold a probable carcinogen that raises estrogen, and a Group 1 carcinogen that blocks it. Awareness was the business plan.

The mammogram: the numbers from the trials, not the poster

Get screened, says every pink poster. Here is what the trials say when you read them instead. The Cochrane review of screening mammography, the most rigorous independent summary there is: for every 2,000 women invited to screening for 10 years, one avoids dying of breast cancer. Ten healthy women, who would never have been diagnosed without screening, are treated as cancer patients anyway. More than 200 live through a false alarm. The adequately randomized trials found no effect on total cancer deaths or on deaths from any cause, and the screened groups had 31 percent more lumpectomies and mastectomies. The Canadian National Breast Screening Study followed 89,835 women for 25 years: 180 breast cancer deaths with annual mammograms, 171 without. No benefit, and 22 percent of the cancers it found were overdiagnosed, one for every 424 women screened. Our own library holds the overdiagnosis literature: the randomized trials show persistent excess incidence after lead time is accounted for [7]; DCIS, stage zero, is about 20 percent of what screening finds, and only about half of untreated cases ever progress over four decades [8]; in Norway, screened and unscreened women ended up with no significant difference in cumulative incidence [9]. The other side ships too: estimates as low as 1 to 5 percent overdiagnosis from service screening [10], and a Korean cohort where follow-up mammography after a diagnosis cut mortality 28 percent [11]. The argument is about how big the harm is, not whether it exists.

• Start annual mammograms at 40 and your chance of at least one false positive in the first 10 years is 61 percent. Your chance of a false-positive biopsy recommendation is 7 percent (Hubbard, Annals of Internal Medicine, 2011).
• The radiation itself: the modeling study done for the US Preventive Services Task Force projected 15 to 35 deaths per 100,000 women from cancers caused by screening mammography, highest in women with large breasts who need extra views (Miglioretti, 2016).
• The biopsy needle moves cells. In a 1999 series, malignant cells were displaced along the needle track in 32 percent of patients after core biopsy, 42 percent when surgery followed within 15 days. A 2009 systematic review put it at 22 percent, range 2 to 63, and noted local recurrence did not differ from excisional biopsy, which is why the field calls it manageable. Both halves reported. Nobody tells you before the needle goes in, and they will biopsy the same spot again next year.
• So the pipeline is: a test that finds ten harmless lesions for every life it saves, a false-alarm rate most women hit in a decade, a needle that moves cells, a diagnosis, and a woman who is now a patient inside a system that bills by the procedure. That is not prevention. That is intake.

Birth control is on the carcinogen list

This is the one almost no woman has been told. The World Health Organization's cancer agency, IARC, lists combined estrogen-progestogen oral contraceptives as Group 1: carcinogenic to humans. Same group as tobacco smoke and asbestos. Monograph 100A names the cancers: breast, cervix and liver. The same monograph says the pill lowers endometrial and ovarian cancer risk, and we say that too, because the charter of this library is that both directions ship. Then the modern numbers. The Danish national cohort followed 1.8 million women for 10.9 years: current and recent users of hormonal contraception had a 20 percent higher breast cancer risk than never-users, rising with duration, about 13 extra breast cancers per 100,000 women a year (Mørch, New England Journal of Medicine, 2017). A 2023 UK study and meta-analysis found the same 20 to 30 percent increase for progestogen-only methods too, pill, injection, implant and hormonal IUD alike [12]. Cervical cancer: among women carrying HPV, 5 to 9 years on the pill nearly tripled the risk and 10 years or more quadrupled it [13]. Liver: the pill is the recognized cause of hepatocellular adenoma, and some of those turn malignant. And it is not only cancer. In the Danish registries, teenage girls on the combined pill were 1.8 times as likely to start an antidepressant, 2.2 times on progestin-only pills (JAMA Psychiatry, 2016); users had roughly double the rate of a first suicide attempt and three times the rate of completed suicide [14]. Injectable medroxyprogesterone, the Depo shot, carried 5.5 times the odds of a brain meningioma needing surgery after a year or more of use [15]. Our library carries the umbrella review that lists oral contraceptive use among the determinants of breast cancer across 35 meta-analyses [16], the ovarian-cancer review where the pill lowers risk [17], and an Italian cohort where it ran the other way for breast cancer [18]. All of it shown. A Group 1 carcinogen is handed to girls at 15 as routine, for decades, with a pink ribbon on the box, and the word awareness nowhere near it.

The tampon

The ribbon is printed on the box. Here is what is in it. In 2024 researchers at UC Berkeley tested 30 tampons from 14 brands and found 16 metals. Lead was in every single one. Arsenic. Cadmium. Lead ran higher in conventional brands, arsenic higher in organic ones (Shearston, Environment International). A UK test the same year found glyphosate, the weedkiller the WHO calls a probable carcinogen, in a box of tampons at 40 times the legal limit for drinking water. Our library holds the wider picture: a 2024 systematic review of 15 studies found phthalates, parabens, phenols and fragrance chemicals in tampons and pads and called it an often-overlooked route of chemical exposure to reproductive tissue [19]; extracts from 18 tampon brands showed estrogen-mimicking activity in nearly half, organic or not [20]; every one of 16 sanitary pads and 7 panty liners tested in South Africa contained parabens, phthalates and bisphenols [21]; PFAS turned up across 91 personal-hygiene products, and skin absorption from a diaper or a cup exceeded house dust [22]; a 2024 synthesis tied urinary glyphosate to breast cancer risk, endocrine disruption and altered DNA methylation in humans [23]. The tissue these products touch is not skin. It absorbs. Nobody asked you. And some of the proceeds go to the marketing of awareness.

The makeup: she is not enough without it

Then we hand her the makeup, and the message underneath it: you are not enough as you are. Permanent hair dye: 8 percent higher breast cancer risk across 17 studies [24], 18.8 percent across eight case-control studies [25]. Chemical relaxers: nearly double the uterine cancer in the same review [24]; the NIH Sister Study of 33,000 women put the lifetime risk at 4.05 percent for frequent users against 1.64 percent for never-users (JNCI, 2022), and hair products track with ovarian cancer in the same cohort [26], with chemical straighteners and incident uterine cancer in the Sister Study itself [27]. Parabens, the preservative in the lotion and the mascara: two 2025 genetic-causation studies tie methylparaben and n-butylparaben to breast cancer through named signaling pathways [28] [29]. Phthalates, the fragrance carrier: higher urinary levels tracked with breast cancer in Mexican women [30] and in Indian women [31], and a Danish national cohort tied phthalate exposure to breast cancer incidence [32]. The single best argument for prevention is one experiment: in 2023, women simply stopped using daily personal-care products containing parabens and phthalates, and the cancer-associated changes in their own breast tissue reversed [33]. Both directions, as always: antiperspirant studies are inconsistent [34], a 2025 review found no increased breast, ovarian or uterine cancer from relaxers across seven cohorts of Black women [35], and one meta-analysis found no BPA association [36]. The direction of the whole shelf is not in doubt, and the burden of proof was never put on the people selling it.

• And when the makeup is not enough, the body itself. In October 2021 the FDA put a black-box warning on every breast implant sold in the United States: a lymphoma called BIA-ALCL, 573 reports and 33 deaths at that time, plus the fatigue, joint pain, brain fog and memory loss patients call breast implant illness.
• A 10-year study of one implant line found capsular contracture rising about 1 percent a year and a 5.7 percent rupture rate on MRI [78]. A 2026 review lays out the mechanism: chronic foreign-body inflammation, silicone gel bleed, macrophage activation [79].
• Teach a girl she is not enough, sell her the fix, and the fix carries the risk. Every step has a receipt.

The diaper

Her exposure started before she could walk. In 2019 the French safety agency ANSES tested 23 diapers and found about 60 potentially harmful substances: glyphosate, dioxins, furans, PCBs, formaldehyde, PAHs, fragrance chemicals, some above safe limits over a realistic 4,000 diapers in the first three years. It was the first such test by any national safety body in the world. Since then: volatile organic compounds in all 31 US diapers and wipes tested, with benzene in some baby diapers [37]; phthalate levels in diapers tracking phthalate metabolites and a DNA-damage marker in infant urine, with skin absorption estimated at up to 45 percent of total exposure [38]; bisphenols in nearly half of 109 daycare diaper urine samples, with the BPA-free substitutes BPS and BPF found more often than BPA itself [39]; phthalates measured across childhood tracking with earlier puberty and smaller uterine volume at 14 in girls [40].

The vial: known carcinogens, tested by every route except the one they use

Before she is two she has been injected dozens of times, and the ingredient list is a public document. The CDC's own excipient table lists formaldehyde in 24 products across 14 vaccine families; IARC classifies formaldehyde as carcinogenic to humans [41], and the occupational record is not subtle: myeloid leukemia deaths rose with peak exposure in formaldehyde-industry workers, relative risk 3.46 at the highest level [42], and 3.1 times in embalmers with the longest exposure [43]. Beta-propiolactone, used to inactivate the virus in some influenza and rabies vaccines, has been a laboratory carcinogen since the 1950s. Glutaraldehyde, in several DTaP combinations, has a published genetic-toxicity and carcinogenicity record by inhalation and skin. Thimerosal, ethylmercury, still in multi-dose flu vials, with its own toxicology comparison against methylmercury [44]. Aluminum adjuvants, whose pediatric toxicity mechanisms are argued in the literature [45] and whose comparative safety summary admits the evidence gaps [46]; polysorbate 80, 2-phenoxyethanol, phenol, octoxynol. Every one of those has toxicology by mouth, by skin or by breath. Here is the point Ryan makes, and it is the point of this section: you will not find the injection studies for these chemicals, because they were never run. The only safety assessment of injected residual formaldehyde in infants is a 2013 computer model, not a measurement in a single child [47]. The other direction ships: a UK cohort of 109,863 children found no link between thimerosal and neurodevelopmental disorders [48], and a 2026 review reports injected aluminum is slowly absorbed and cleared with no association found with autism or neurotoxicity [49], while sheep given two adjuvanted doses still carried crystallized aluminum inside macrophages 133 days later [50]. A carcinogen by inhalation, a carcinogen by ingestion, and a shrug by injection is not a safety record. It is an absence of one. Our write-up on where a child meets formaldehyde, with the CDC table page by page, is linked below.

The cleaning cabinet: 2.1 times

The one study that asked the question directly: the Cape Cod Breast Cancer and Environment Study interviewed 787 women with breast cancer and 721 without. Women in the top quarter of cleaning-product use had 2.1 times the breast cancer risk of the bottom quarter; combined air-freshener use, 1.9 times; solid slow-release air fresheners and mold removers stood out [51]. Nobody put it on a box. Women in jobs with high exposure to carcinogens and endocrine disruptors carried 1.42 times the risk across 1,005 cases, and premenopausal risk in automotive plastics was 4.76 times [52]. Immigrant women, who disproportionately clean houses and staff hospitals, face elevated exposure to phthalates, antimicrobials and other mammary-gland toxicants carried in fragrance [53]. Now the ingredients, one at a time.

• Formaldehyde and industrial air toxics: in 53,000 California women, residential exposure to dichloromethane, tetrachloroethylene, trichloroethane and formaldehyde raised breast cancer risk [80]; synthetic air fresheners emit formaldehyde, benzene, toluene and xylene [81]; free formaldehyde was found in 88.6 percent of 35 cosmetics, none labeled [82].
• Benzene: occupational exposure raised breast cancer risk in a 2024 meta-analysis [83] and cervical, ovarian and endometrial cancer in a 2025 one [84].
• Nonylphenol, the breakdown product of common detergent surfactants: promoted breast cancer growth in the laboratory across a 58-study review, with some null studies alongside [85].
• Quaternary ammonium disinfectants, the quats in disinfecting wipes and sprays: cut fertility in mice through both male and female reproductive processes [86], with a 2024 review of their reproductive and developmental toxicity [87].
• Triclosan: linked to lower ovarian reserve [88] and to hormone imbalance in polycystic ovary syndrome [89]. Cadmium: the most consistent endocrine disruptor tied to endometrial cancer across two 2026 reviews [90] [91].
• Talc: the Sister Study, with bias correction, put genital talc at 1.17 to 3.34 times the ovarian cancer hazard (JCO, 2024); the FDA's own adverse-event file holds 4,427 cosmetic-product cancer reports, mostly talc and ovarian cancer [92]; a 2026 meta-analysis finds the case-control studies positive and the cohorts null, so we say that too [93].
• The lungs, for good measure: weekly use of scented, irritant and disinfecting-wipe products tracked with asthma in 41,570 French adults [94]; occupational cleaners carry 50 percent higher asthma and 43 percent higher COPD risk across 21 studies [95].
• Every one of these can carry a pink ribbon in October.

Follow the money, because it does not hide

Nonprofit hospitals are the largest business in most American towns, tax-exempt because they promise charity care. The Lown Institute compared what 2,425 of them saved in tax breaks to what they gave back. Eighty percent gave back less than they saved. The gap: $25.7 billion in one year. A sick woman is revenue. A well woman is not. That is not a conspiracy; it is the billing model, and it is why a ribbon that said prevention had to be repainted. Charlotte Haley's postcard said 5 percent of the cancer budget went to prevention. That was 1991. Ask what the number on this October's pink box is.

B17: the one they buried on purpose

There are books on this and they are hard to find, which is the point: World Without Cancer (G. Edward Griffin, 1974), Alive and Well (Dr. Philip Binzel, 1994, one physician's clinical series), The Cancer Industry (Ralph Moss). The Hunza people of the Karakoram ate apricot kernels as a staple and pressed the oil, and the British physician Sir Robert McCarrison wrote them up in the 1930s as a population without the diseases he saw everywhere else. That is lineage evidence, and in this library lineage is evidence. Then the part that was buried, with names. From 1972 to 1977 Kanematsu Sugiura, a senior scientist at Memorial Sloan-Kettering, ran amygdalin in mice with spontaneous breast tumors and reported that it significantly inhibited lung metastases and slowed the primary tumors. His supervisor's words for why it went unpublished: it would have caused all kind of havoc. The results leaked in 1973. Sloan-Kettering's 1977 press release said laetrile showed no benefit. Ralph Moss, the center's science writer, said publicly that the results were being suppressed, and was fired. That is the institution's own history. What the laboratory says today: amygdalin triggers programmed cell death in triple-negative breast cancer cells (2016), selectively sensitizes breast cancer cells to oxidative stress (2019), cuts adhesion and migration in MDA-MB-231 and MCF-7 lines (2021), and in nanoparticle form shrinks breast tumors and sharpens radiotherapy (2023); Europe PMC holds 71 papers with amygdalin and cancer in the title. Our library holds a 2026 mouse study where an amygdalin nanocomposite reduced tumor volume and improved survival [54] and a rat model where apricot-seed extract and amygdalin reduced tumor markers in chemically induced liver cancer [55].

• Now the other side, because the charter says it ships. The only human trial is Mayo Clinic, 1982, 178 patients: no benefit, and cyanide in the blood at levels approaching lethal (Moertel, New England Journal of Medicine). The Cochrane review found no eligible human studies at all. Our library carries a woman who took amygdalin tablets for cancer and arrived with severe cyanide poisoning [96], and the 1983 finding that high-dose vitamin C decreases the body's detoxification of the cyanide amygdalin releases [97]. Kernels plus a vitamin C megadose makes the poison worse.
• So here is the honest sentence. One human trial in 44 years. A compound with a documented metastasis signal in a Sloan-Kettering lab, a laboratory literature that keeps growing, a lineage behind it, and nobody has funded a second human trial since 1982 because nobody can patent an apricot. That is what buried looks like. It is also why you cannot know whether it works in a person, and why a nurse will tell you the cyanide is real. Both things are true.

Bee venom: 2,400 years of use, 240 cancer papers, zero human trials

Hippocrates recorded bee stings as medicine around 400 BC. Galen wrote about bee venom. Charlemagne and Ivan the Terrible were stung on purpose for gout. Chinese, Korean, Egyptian and Russian traditional medicine all carry it; Philipp Terč published on bee stings and rheumatism in 1888; Korean traditional medicine still runs bee venom acupuncture under 18 clinical guidelines [56]. The laboratory record is not thin: Europe PMC holds 240 papers with bee venom or melittin in the title alongside cancer. In 2003 bee venom inhibited mammary carcinoma cells in the dish and tumor growth in living mice (Toxicon). In 2020 the Harry Perkins Institute tested the venom of 312 honeybees on breast cancer lines: melittin destroyed triple-negative and HER2-enriched cells within 60 minutes at concentrations that left normal cells mostly untouched (npj Precision Oncology). Our library: melittin drives self-destruction in cancer cells while preserving mitochondria in normal cells [57]; a 2024 review found it killed liver, lung, bladder, kidney, prostate and leukemia cells more readily than normal cells [58]; nanocarrier delivery is the active front because raw venom is toxic and allergenic [59] [60]. The other side: the 145-study safety review found adverse events in a median 28.9 percent of patients, and bee venom acupuncture carried 3.6 times the risk of a saline injection [61]. Anaphylaxis is real, and no route or dose for people has been established [58]. Twenty-four centuries of use, a growing literature, and not one human cancer trial. Same shape as B17. Same reason.

Pine needle: the tree of life

In the winter of 1535 Jacques Cartier's crew lay dying of scurvy on the frozen St. Lawrence, 25 already dead. The Iroquois at Stadacona brought boughs of a conifer they called annedda, showed them how to brew the bark and needles, and the crew recovered within days. Cartier named it arbre de vie, the tree of life. Indigenous peoples across the continent drank conifer-needle tea long before anyone wrote it down; in Korea it is solip-cha, a named medicine; Taoist priests drank it for long life, and Chinese texts from the Tang through the Ming carry dozens of pine-needle prescriptions. The laboratory has been catching up: Korean red pine needles were antioxidant, antimutagenic and antitumor in 2006 [62] and protected DNA from oxidative damage in 2009; Scots pine extract and essential oil were selectively toxic to estrogen-insensitive breast cancer cells in 2015 [63], with a 2026 mechanistic follow-up; pine needle essential oil suppressed tumor progression through the AMPK/mTOR pathway in 2018. Pine needles are the richest natural source of shikimic acid, the starting material for Tamiflu. Pine bark has real human trials in our library: 12 weeks of it in postmenopausal women raised antioxidant capacity and lowered oxidative damage against placebo [64], and it lowered an oxidative-stress marker in healthy older adults [65]. Three cautions, because a nurse says them. Pine needles are documented abortifacients in cattle, so the tea is not for pregnancy. One 2019 cell study found shikimic acid promoted estrogen-receptor-positive breast cancer cell proliferation, so the whole tea the lineage tested is not the same thing as an extract. And white pine itself has no cancer study on our shelf; the species in the papers are Korean red pine and Scots pine. That is a gap in our library, not in the tree.

A frog, and the fruit they warn you about

In July 2026 a Japanese team gave mice with colorectal tumors one intravenous dose of Ewingella americana, a bacterium from the gut of the Japanese tree frog. Every tumor disappeared. It beat checkpoint immunotherapy and liposomal doxorubicin head to head, with no damage to healthy tissue (Gut Microbes). Mice. One study. An un-patentable organism that outperformed two billion-dollar drug classes got a week of science-news coverage and nothing on a pink box. Soursop: the fruit's acetogenins shut down mitochondrial complex I in cancer cells and are cytotoxic to multiple cancer lines in the laboratory [66]; the same acetogenins, especially annonacin, are neurotoxins, and heavy consumption is linked to an atypical Parkinson's disease on Guadeloupe. Laboratory benefit, documented human harm at high intake. And the free levers, each with a library row: fibrocystic breast disease responded to molecular iodine in the 1993 Ghent and Eskin series [67] and a 2017 randomized trial of 188 women found a GLA-iodine-selenium formula reduced breast nodularity [68]; light at night tracks with higher breast cancer risk across 19 studies [69] and one hour of summer sun a day with lower risk [70]; sugar-sweetened drinks tracked with higher risk across 27 studies [71]; even one alcoholic drink a day raised breast cancer risk in two large US cohorts [72]; in hormone-positive breast cancer a low-glycemic Mediterranean diet plus a daily brisk walk cut metabolic syndrome by 65 percent [73], and an 8-week whole-food plant-based diet in metastatic disease dropped insulin 33 percent [74]. None of this treats cancer. All of it is prevention. None of it fits in a pink box.

Anemia: the proof they never cared

If you want one number that shows how the system has treated women for decades, it is not a cancer number. 38.6 percent of American girls and young women aged 12 to 21 are iron deficient. That is a 2023 JAMA analysis of national survey data, and 84 percent of them were not anemic, so a standard blood count missed them. They were tired, foggy, cold, losing hair, and told that was being a teenage girl. Correcting low iron stores, even without anemia, improves mood and cognition [75]. Low iron holds thyroid function down on its own, because the thyroid's key enzyme needs iron to work [76]. Nobody put a ribbon on it. There is no awareness month for the most common nutrient deficiency in women on earth, because the fix costs almost nothing and the symptoms get a woman a prescription for an antidepressant instead. The same system that let 4 in 10 girls run on empty is the one telling women they are strong for surviving a cancer that most of the evidence above says was substantially preventable. Strong is what you call someone after you have failed them. We built the Lab Library so you can check this yourself: ferritin, not just hemoglobin, and what normal actually means on a range built from a population that was already deficient.

One more thing about daughters

Every mitochondrion in your body came from your mother. The egg carries them; the sperm's do not survive. The energy factories in your cells are a maternal inheritance, and the library shows what travels with them: in an animal model, a mother's metabolic syndrome programmed mitochondrial dysfunction across three generations through the germline [77]. What we put into a girl, through the diaper, the shot, the pill, the tampon, the makeup, the implant, the cleaning spray, the sugar and the screen at midnight, is not only her exposure. It is her daughter's starting point. That is what Charlotte Haley meant by prevention. That is what the peach ribbon said before the lawyers changed the color.

What to do with this

Prevention > awareness. Five moves, none of them in a box.

• Read your own labs. Ferritin, thyroid, inflammation, hormones. The Lab Library is free and explains each marker in plain English with the studies attached.
• Know what you are being prescribed. Birth control is a Group 1 carcinogen by the WHO's own classification. Ask for the absolute numbers, the non-hormonal alternatives, and read the monograph yourself; it is linked below.
• Clear the cabinet. Fragrance-free, paraben-free, phthalate-free, no quats, no solid air fresheners, and fewer products altogether. The breast-tissue reversal study says the body responds fast.
• Know the screening numbers before you consent. One in 2,000 saved, ten overtreated, 200 false alarms, 61 percent false-positive odds in a decade. Ask for the absolute numbers and the alternatives.
• Fix the free levers first. Sun in the morning, dark at night, a daily walk, less sugar, less alcohol, iodine and iron checked. Then ask what the ribbon bought, and ask the company selling it what is in the box.